Clazakizumab vs placebo or usual care
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.12 [0.2, 6.24]1 study · 17 participantsLow